The health secretary, Vice President JD Vance and other top officials addressed a conference sponsored by corporations, including A.I. companies and others with business before the government.
Robert F. Kennedy Jr. in Dallas this month. His wholehearted endorsement of A.I. comes as the Trump administration is facing mounting pressure to do more to regulate the technology.
President Trump’s meetings with tech leaders produced some voluntary safeguards and a commitment to rebrand artificial intelligence as “super intelligence,” the term that Mr. Trump prefers.
President Trump’s meetings with tech leaders produced some voluntary safeguards and a commitment to rebrand artificial intelligence as “super intelligence,” the term that Mr. Trump prefers.
An Editor at Large: The head of state of the least populous country, Pope Leo XIV, is neither grotesque nor greedy, and his pilgrimage to secular France, 'That The World May Have Life,' is encouraging a religious reconnection with God.
Robinhood said on Tuesday it will let users trade some US stocks round-the-clock during weekends, marking its latest effort to keep up as the industry marches toward 24-hour access.
Riders experienced up to four times the force of gravity on X2 at Six Flags Magic Mountain in Valencia, Calif. The ride had attracted criticism and lawsuits claiming it caused severe injuries.
Researchers published late-stage clinical trial data today for the latest obesity drug, retatrutide—expected to be the most powerful formula yet—and the results appear in line with high expectations. Patients with obesity on the highest retatrutide dose lost an average of 25 percent of their body weight after 80 weeks, and an average of 30 percent after an extension period to 104 weeks. Overall, more than a third of participants taking retatrutide lost 30 percent or more of their weight.
The drug also proved effective at reducing knee pain (by up to 62 percent) in a subset of participants with obesity-linked knee osteoarthritis. It reduced the number of sleep apnea events per hour (by up to 57 percent) in a subset of participants with obesity-linked obstructive sleep apnea. The drug improved cardiometabolic measurements across the board, including blood pressure, triglycerides, and low-density lipoprotein cholesterol (bad cholesterol). At the start, more than a third of trial participants had prediabetes and, by the end, the condition had resolved in more than 90 percent of those participants.
The trial began in 2023 and included 2,339 participants from 131 clinical trial sites in 11 countries. Participants were broken into four nearly equal groups, given either: 4 mg of retatrutide, 9 mg, 12 mg, or a placebo. Across all groups, the average starting weight was around 113 kg (250 pounds), and the average body mass index (BMI) was 40. For the subset analyses, 574 participants had knee osteoarthritis, and 243 had obstructive sleep apnea. The results appeared today in the New England Journal of Medicine.
Goldman Sachs' private credit fund said on Tuesday that investor requests to pull money further slowed down in the third-quarter tender offer, with redemption pressure easing across the broader industry.
Login
